Search details
1.
Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial).
J Antimicrob Chemother
; 79(6): 1380-1384, 2024 Jun 03.
Article
in English
| MEDLINE | ID: mdl-38656448
2.
DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
J Antimicrob Chemother
; 2024 Jun 17.
Article
in English
| MEDLINE | ID: mdl-38884154
3.
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022.
Euro Surveill
; 29(11)2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38487889
4.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clin Infect Dis
; 76(5): 861-870, 2023 03 04.
Article
in English
| MEDLINE | ID: mdl-36259527
5.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Clin Infect Dis
; 77(7): 991-1009, 2023 Oct 05.
Article
in English
| MEDLINE | ID: mdl-37207617
6.
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study.
Clin Gastroenterol Hepatol
; 21(3): 713-722.e3, 2023 03.
Article
in English
| MEDLINE | ID: mdl-35436624
7.
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
J Antimicrob Chemother
; 78(3): 769-778, 2023 03 02.
Article
in English
| MEDLINE | ID: mdl-36659824
8.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
J Antimicrob Chemother
; 78(9): 2361-2365, 2023 09 05.
Article
in English
| MEDLINE | ID: mdl-37539492
9.
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.
J Antimicrob Chemother
; 78(6): 1510-1521, 2023 06 01.
Article
in English
| MEDLINE | ID: mdl-37104815
10.
Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis.
PLoS Pathog
; 17(4): e1009526, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33872329
11.
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.
Br J Clin Pharmacol
; 89(4): 1318-1328, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36680782
12.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Crit Care
; 27(1): 9, 2023 01 10.
Article
in English
| MEDLINE | ID: mdl-36627655
13.
HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection.
J Infect Dis
; 225(1): 116-120, 2022 01 05.
Article
in English
| MEDLINE | ID: mdl-34166492
14.
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study.
J Antimicrob Chemother
; 77(12): 3427-3435, 2022 11 28.
Article
in English
| MEDLINE | ID: mdl-36205009
15.
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
J Antimicrob Chemother
; 77(7): 1980-1988, 2022 06 29.
Article
in English
| MEDLINE | ID: mdl-35411401
16.
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.
Eur J Clin Microbiol Infect Dis
; 41(3): 445-454, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34997388
17.
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study.
BMC Infect Dis
; 22(1): 540, 2022 Jun 13.
Article
in English
| MEDLINE | ID: mdl-35698029
18.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
J Antimicrob Chemother
; 76(9): 2380-2393, 2021 08 12.
Article
in English
| MEDLINE | ID: mdl-34120186
19.
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
J Antimicrob Chemother
; 76(2): 477-481, 2021 01 19.
Article
in English
| MEDLINE | ID: mdl-33099638
20.
Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial).
Br J Clin Pharmacol
; 87(4): 1930-1939, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33010058